Biochemical and Biophysical Research Communications

2001

DOI: 10.1006/bbrc.2001.4661

|View full text |Cite

|

Sign up to set email alerts

|

IgE Binding Properties of the Recombinant Ovomucoid Third Domain Expressed in Escherichia coli

¹

,

²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

0

Mentioning

1

Contrasting

0

Year Published

2003

2003

2006

2006

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 7 publications

(1 citation statement)

References 25 publications

(24 reference statements)

Supporting

0

Mentioning

1

Contrasting

0

Order By: Relevance

“…The third domain of ovomucoid has been shown to be more allergic than the first and the second domain (5). The recombinant ovomucoid third domain antigen shows molecular and immunological properties comparable with its native counterpart (6). We have recently shown that modified (engineered) isoform of ovomucoid has lower IgE‐binding reactivity against egg allergic patient's sera (7).…”

mentioning

confidence: 94%

Engineered recombinant ovomucoid third domain can desensitize Balb/c mice of egg allergy

¹

,

²

2006

View full text Add to dashboard Cite

The purpose of this study was to determine the in vivo desensitization efficacy of a hypoallergenic variant of egg white ovomucoid third domain (DIII) in Balb/c mice model. We mapped the immunodominant B-cell epitopes of ovomucoid in Balb/c mice. A hypoallergenic ovomucoid third domain (GMFA) mutant isoform having ablated allergenicity against egg allergic patient's sera was used to desensitize DIII-sensitized Balb/c mice by intraperitoneal injections. Ovomucoid DIII generated high levels of plasma histamine and specific immunoglobulin (Ig)E levels, and increased Th2 type cytokine (IL-4). On the other hand, the allergic response of mice desensitized with the GMFA was found to be significantly inhibited and abrogated by prevention of anaphylaxis reactions, low histamine levels and increased Th1-type cytokine (INF-gamma). It was found that significantly higher levels of IL-10 and IL-12 were secreted in the desensitized group. Desensitization with the GMFA antigen also suppressed synthesis of DIII specific-IgE levels and enhanced specific IgG2a and IgG levels compared with the group treated with the DIII antigen. The present results indicated that hyposensitization with the GMFA can desensitize or down-regulate the allergic response in Balb/c mice and this hypoallergenic variant of ovomucoid DIII can shift an ongoing allergen-specific Th2 response towards a Th1 skewed response.

“…The third domain of ovomucoid has been shown to be more allergic than the first and the second domain (5). The recombinant ovomucoid third domain antigen shows molecular and immunological properties comparable with its native counterpart (6). We have recently shown that modified (engineered) isoform of ovomucoid has lower IgE‐binding reactivity against egg allergic patient's sera (7).…”

mentioning

confidence: 94%

Engineered recombinant ovomucoid third domain can desensitize Balb/c mice of egg allergy

¹

,

²

2006

View full text Add to dashboard Cite

The purpose of this study was to determine the in vivo desensitization efficacy of a hypoallergenic variant of egg white ovomucoid third domain (DIII) in Balb/c mice model. We mapped the immunodominant B-cell epitopes of ovomucoid in Balb/c mice. A hypoallergenic ovomucoid third domain (GMFA) mutant isoform having ablated allergenicity against egg allergic patient's sera was used to desensitize DIII-sensitized Balb/c mice by intraperitoneal injections. Ovomucoid DIII generated high levels of plasma histamine and specific immunoglobulin (Ig)E levels, and increased Th2 type cytokine (IL-4). On the other hand, the allergic response of mice desensitized with the GMFA was found to be significantly inhibited and abrogated by prevention of anaphylaxis reactions, low histamine levels and increased Th1-type cytokine (INF-gamma). It was found that significantly higher levels of IL-10 and IL-12 were secreted in the desensitized group. Desensitization with the GMFA antigen also suppressed synthesis of DIII specific-IgE levels and enhanced specific IgG2a and IgG levels compared with the group treated with the DIII antigen. The present results indicated that hyposensitization with the GMFA can desensitize or down-regulate the allergic response in Balb/c mice and this hypoallergenic variant of ovomucoid DIII can shift an ongoing allergen-specific Th2 response towards a Th1 skewed response.

Genetic attachment of undecane peptides to ovomucoid third domain can suppress the production of specific IgG and IgE antibodies

¹

,

²

2003

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Engineered recombinant ovomucoid third domain can modulate allergenic response in Balb/c mice model

¹

,

²

2006

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.